ETER100 renal safety analysis clears combo of no added kidney toxicity
A secondary analysis of the Phase 3 ETER100 trial shows benmelstobart plus anlotinib matched sunitinib on renal injury measures, but the trial's PFS primary endpoint result remains undisclosed.
Executive Summary
- A secondary analysis from the ETER100 Phase 3 trial (NCT04523272) reports that benmelstobart plus anlotinib caused no more renal injury than sunitinib monotherapy in first-line advanced renal cell carcinoma, and kidney abnormalities did not predict survival outcomes.
- The abstract does not report the trial's registered primary endpoint, progression-free survival by independent review committee, so the combination's core efficacy claim against sunitinib remains unresolved for readers of this analysis.
- No AppliedXL model probability exists for this event; the seed carried no pre-event read to grade against a safety subanalysis that was never the trial's primary readout.
- Two direct PD-L1-targeting comparators in renal cell carcinoma, SHR-8068 and Pumitamig, remain in early Phase 1/2 development, leaving TQB2450 among the more advanced PD-L1 combination assets in this indication despite a declining overall field.
- The renal-safety parity finding removes one hypothetical tolerability concern for the regimen but does not change the program's probability of success on its efficacy question, since that depends on the still-undisclosed PFS data.
The analysis
The abstract, published July 2, 2026, analyzes renal function in all randomized, treated patients from the ETER100 trial (NCT04523272), a Phase 3 study comparing benmelstobart plus anlotinib against sunitinib monotherapy in 528 patients with treatment-naive advanced renal cell carcinoma NCT04523272+1A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerNCT04523272Press ReleaseJul 2, 2026. The paper states its aim directly: "data on treatment-emergent renal injury during combination therapy and its prognostic implications remain limited," and the analysis was designed to close that gap Press ReleasePress ReleaseJul 2, 2026. It reports no statistically significant difference between arms in serum creatinine elevation (p=0.0538), percentage or absolute decrease in creatinine clearance (p=0.2546 and p=0.7343), or proteinuria (p=0.0728) Press ReleasePress ReleaseJul 2, 2026.
What it does not answer
The trial's registered primary endpoint is progression-free survival evaluated by independent review committee, assessed over a 60-week window NCT04523272A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerNCT04523272. This abstract does not report that result. It also does not report overall survival, disease control rate, or duration of response, all of which are registered secondary endpoints NCT04523272A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerNCT04523272. No results have been posted to ClinicalTrials.gov for this trial. The renal-safety finding is real and specific, but it answers a tolerability question, not the efficacy question that determines whether this combination is competitive against sunitinib.
Recovery and risk factors
Among patients who developed serum creatinine elevation during combination therapy, 64.00% (64 of 100) had recovered to normal levels and 6.00% (6 of 100) showed improvement as of January 2024 Press ReleasePress ReleaseJul 2, 2026. For proteinuria, 45.56% (77 of 169) recovered fully and 22.49% (38 of 169) improved Press ReleasePress ReleaseJul 2, 2026. Multivariate analysis identified a history of nephrectomy and a baseline estimated glomerular filtration rate below 90 mL/min/1.73 m2 as independent predictors of creatinine elevation, and multivariate Cox regression found neither creatinine elevation nor proteinuria was an independent risk factor for progression-free or overall survival Press ReleasePress ReleaseJul 2, 2026.
Trial's operational path
The road to this analysis included a 731-day cumulative delay in primary completion date, from June 2023 to June 2025, alongside a 26.3% increase in enrollment target from 418 to 528 patients, both logged in October 2024. The trial's status moved from Unknown to Active, not recruiting in the same update, and registry records show no further update for over 300 days after that, a pattern flagged as a dormancy signal in protocol stability tracking. That history frames the safety abstract as one output from a trial whose primary readout has taken years longer than its original registered timeline suggested.
Where TQB2450 stands competitively
Among PD-L1-targeting drugs advancing in renal cell carcinoma, the closest direct comparators are SHR-8068, a monoclonal antibody from Suzhou Suncadia Biopharmaceuticals, and Pumitamig, a PD-L1 bispecific antibody from Bristol-Myers Squibb, both still in Phase 1/2. TQB2450 sits at Phase 3, ahead of both on development stage. The broader PD-L1 field, however, shows declining activity in the target-by-indication combination, with 193 recent trials against 1,239 older ones, a ratio of 0.13 that the landscape data label a decelerating field. No completed, terminated, or withdrawn Phase 3 trial of TQB2450 with PD-L1 targeting in renal cell carcinoma exists in historical outcomes data, leaving no direct precedent to benchmark this program's odds.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.